InvestorsHub Logo
Followers 68
Posts 5584
Boards Moderated 0
Alias Born 01/13/2012

Re: investordisciple post# 20099

Saturday, 03/17/2012 10:14:54 AM

Saturday, March 17, 2012 10:14:54 AM

Post# of 331133
It can't be much better than this fellow Whelan having them both up on the table with the most to lose. Unfortunately for investors, maybe yes, maybe no, that he seems to be learning on the fly and apparently has made a few mistakes, but I saw the pics of Dubai - this man has years of experience, staff and lawyers AND applications inside FDA on products similar to, or exactly the same as, RecoveryRx on which BIEL already has FDA approval.

Does anyone think for one second that Whelan and everyone else inside BIEL isn't crawling out of their skin with impatience? I sure would be, I'm twitching thinking about it. And the ALLAY application covers menstrual pain and cramps for women who will no longer have to take drugs every month? Huge market!

I like where we are and the fact that the guy who stands to win the most is the largest shareholder in the company. If I'm CEO of J&J I'm watching this like a hawk. When BIEL gets approval, it's an instant target! And if J&J gets it, J&J just bought an edge on all its drug competitors. Nice place to be.

I know I'm being repetitive, but it just makes no sense to me that a surgeon can prescribe the already approved RecoveryRx for me after he operates on my eye, to promote better, faster recovery/healing and I can wear a RecoveryRX next to my brain and the FDA won't approve ALLAY for women and ActiPatch for aches, pain, sprains, etc. I'm staying right where I am, patiently waiting for approval. Happy St. Pati's Day